The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

There is disclosed a compound Formula I

##STR00001## In Formula I: Z is CR.sup.4R.sup.5, CCR.sup.4R.sup.5, SiR.sup.4R.sup.5, GeR.sup.4R.sup.5, NR.sup.4a, PR.sup.4a, P(O)R.sup.4a, O, S, SO, SO.sub.2, Se; SeO, SeO.sub.2, Te, TeO, or TeO.sub.2; R.sup.1-R.sup.3 are the same or different at each occurrence and are D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl, where two groups selected from R.sup.1, R.sup.2, and R.sup.3 can be joined together to form a fused ring; R.sup.4-R.sup.5 are the same or different at each occurrence and are H, D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl; R.sup.4a is alkyl, silyl, germyl, aryl, or a deuterated analog thereof; a is an integer from 0-4; b and c are the same or different and are an integer from 0-3.

There is disclosed a compound Formula I

##STR00001## In Formula I: Z is CR.sup.4R.sup.5, CCR.sup.4R.sup.5, SiR.sup.4R.sup.5, GeR.sup.4R.sup.5, NR.sup.4a, PR.sup.4a, P(O)R.sup.4a, O, S, SO, SO.sub.2, Se; SeO, SeO.sub.2, Te, TeO, or TeO.sub.2; R.sup.1-R.sup.3 are the same or different at each occurrence and are D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl, where two groups selected from R.sup.1, R.sup.2, and R.sup.3 can be joined together to form a fused ring; R.sup.4-R.sup.5 are the same or different at each occurrence and are H, D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deuterated heteroaryl, deuterated alkyl, deuterated amino, deuterated silyl, or deuterated germyl; R.sup.4a is alkyl, silyl, germyl, aryl, or a deuterated analog thereof; a is an integer from 0-4; b and c are the same or different and are an integer from 0-3.

A set of small molecules ER biomodulators that kill therapy-resistant ER positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I). ##STR00001##

The present invention relates to a novel compound and its use as a fragrance material.

The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

Provided herein are a fused polycyclic compound, and an electronic device having at least one organic layer comprising the fused polycyclic compound as an electroactive compound.

Provided herein are a fused polycyclic compound, and an electronic device having at least one organic layer comprising the fused polycyclic compound as an electroactive compound.

The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: ##STR00001##
wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.